EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid

Takaaki Kawanobe iD, Shinya Asano, Hitoshi Kandori, Masami Aoki, Ajaya Ram Shrestha, Kazuo Sekiguchi, Kotaro Yokoyama, Ryo Fukuda, Tadashi Umemoto

Nucleic Acid Therapeutics · 01.06.2025 · 35 (3) · 114-124

DOI: 10.1089/nat.2024.0047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.06.2025. Verfasst von Takaaki Kawanobe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Luxna Biotech Co., Ltd., Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Liver, Nucleic Acids, Spiro Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amido-bridged nucleic acid (AmNA) and a 2′-O,4′-C-spirocyclopropylene bridged nucleic acid (scpBNA) are bridged nucleic acid analogs with high binding affinity toward complementary strands along with high nuclease resistance. AmNA and scpBNA have been developed to overcome phosphorothioate modified gapmer hepatotoxicity, while the mechanism of reducing hepatotoxicity still remains unknown. Here, we found that antisense oligonucleotides (ASOs) with combination of AmNA, scpBNA, and phosphodiester (PO) bonds could significantly reduce hepatotoxicity in mice. Histopathological findings of the periportal spaces of the liver were observed only in the locked nucleic acid and AmNA-scpBNA groups, but not in the AmNA-scpBNA-PO group. Furthermore, bioinformatics and histopathological analysis revealed that the reduced hepatotoxicity might be related to mitochondrial abnormalities, such as decreased expression levels of Atp5o and Sdhb genes. Taken together, the results of this study demonstrated that AmNA, scpBNA, and PO modification are able to reduce hepatotoxicity for improving the potential of ASOs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseLiverNucleic AcidsSpiro CompoundsAnimalsMiceMaleOligonucleotides

Stichwörter der Autor:innen

AmNAantisense oligonucleotidehepatotoxicityscpBNA

Substanzen

Oligonucleotides, AntisenseNucleic Acidslocked nucleic acidOligonucleotidesSpiro Compounds

Autor:innen und Institutionen

  • Luxna Biotech Co., Ltd., Suita, Osaka, Japan.
  • Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan.

ORCID-Profile: Takaaki Kawanobe

Zitieren

APA

Kawanobe, T., Asano, S., Kandori, H., Aoki, M., Shrestha, A. R., Sekiguchi, K., Yokoyama, K., Fukuda, R., & Umemoto, T. (2025). Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid. Nucleic Acid Therapeutics, 35(3), 114-124. https://doi.org/10.1089/nat.2024.0047

Vancouver

Kawanobe T, Asano S, Kandori H, Aoki M, Shrestha AR, Sekiguchi K, et al. Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid. Nucleic Acid Therapeutics. 2025;35(3):114-124. doi:10.1089/nat.2024.0047

BibTeX
@article{Kawanobe2025,
  author = {Kawanobe, Takaaki and Asano, Shinya and Kandori, Hitoshi and Aoki, Masami and Shrestha, Ajaya Ram and Sekiguchi, Kazuo and Yokoyama, Kotaro and Fukuda, Ryo and Umemoto, Tadashi},
  title = {Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  volume = {35},
  number = {3},
  pages = {114--124},
  doi = {10.1089/nat.2024.0047}
}
Kostenlos starten →